Vascepa Approval and Use in Europe
Vascepa (icosapent ethyl) is approved in Europe under the brand name Vazkepa for reducing cardiovascular risk in high-risk patients with elevated triglycerides, following EMA authorization in 2021.[1] Side effects mirror those reported globally, as the drug's safety profile is based on multinational trials like REDUCE-IT.
Most Common Side Effects
Patients commonly report:
- Atrial fibrillation (about 5% higher incidence vs. placebo).
- Bleeding events, such as epistaxis or bruising (2-3% increased risk).
- Joint pain (arthralgia).
- Gout flares.
- Skin rash or hypersensitivity reactions.
These occur at similar rates in European patients as in US data, with no unique regional differences noted.[1][2]
Serious or Rare Side Effects
Less common but monitored risks include:
- Hemorrhagic stroke (rare, linked to high bleeding risk).
- Retinal vascular disorders.
- Myalgia or muscle spasms.
EMA labeling warns of potential liver enzyme elevations, though these are infrequent (<1%). No new safety signals have emerged from post-marketing European surveillance.[2]
Differences from US Reporting
Vascepa's European label (Vazkepa) aligns closely with FDA data but emphasizes cardiovascular benefits in statin-treated patients. Side effect frequencies are identical in REDUCE-IT subgroup analyses for EU populations. No Europe-specific warnings added as of 2024.[1]
Patient Concerns and Management
Many ask about bleeding risks with anticoagulants—Vascepa increases this modestly, so monitoring is advised. Fish allergy patients should avoid it due to icosapent ethyl derivation. Consult SmPC for full details; report suspected effects via national systems like EudraVigilance.[2]
[1]: EMA Vazkepa Product Information
[2]: Medicines.org.uk Vazkepa SmPC